Explore how peptide science evolved from foundational chemistry to one of the most important therapeutic platforms in modern medicine.
Peptides have moved far beyond their early reputation as technically constrained molecules. This white paper traces the scientific, clinical, and manufacturing milestones that transformed peptides into a major therapeutic class used across endocrinology, oncology, infectious disease, metabolic disorders, cardiovascular medicine, and more. It also explains why the GLP-1 era marks a turning point for peptide innovation, delivery, and large-scale production.
Why Download This White Paper
This paper offers a practical look at how peptide therapeutics reached their current momentum. From Emil Fischer’s peptide bond concept to insulin, oxytocin, vasopressin, solid-phase peptide synthesis, recombinant production, and the rise of GLP-1 receptor agonists, it connects scientific history with today’s development and manufacturing realities.
Key Takeaways Readers Will Gain
- A clear understanding of the major milestones that shaped peptide therapeutics, from early chemistry to modern drug development.
- Insight into why peptides have become important across multiple therapeutic areas, including metabolic disease, oncology, chronic pain, infectious disease, and rare disorders.
- A practical view of how SPPS, recombinant methods, formulation advances, and delivery innovation enabled peptide scale-up and broader clinical use.
- Context for the GLP-1 revolution, including why GLP-1 receptor agonists and dual incretin agents have reshaped diabetes, obesity, and cardiometabolic treatment.
- Perspective on future peptide trends, including more complex molecules, alternative delivery routes, higher regulatory expectations, and deeper integration across development, analytics, formulation, and manufacturing.
This white paper is relevant for professionals evaluating peptide-based therapies, development strategies, manufacturing readiness, supply considerations, and long-term pipeline opportunities across the biopharmaceutical landscape.
Authors: Bob Brousseau and Francisco Gonzalez, PhD